It is generally assumed that when ET and PD co-occur, ET manifests first and PD later. 14, [18] [19] [20] Resting tremor, which is characteristic of PD, may also occur during the late stages in some ET patients. 16, 29, 30, 35 Action tremor, which is the diagnostic feature of ET, is also present in some PD patients. 36 Additionally, the clinical features of ET and PD each evolve over time. 16, [37] [38] [39] These overlapping phenotypes make identification of PD difficult, in ET patients. Bradykinesia and rigidity are two other motor manifestations of PD that are not part of ET. These are therefore important clinical considerations, for a PD diagnosis in ET patients.
Several clinical and epidemiological studies have reported on the ET-PD co-prevalence. 6, 14, 21, 23 Significance of such studies is limited because the brain pathology was not identified. One clinicopathological study suggested an increased risk of PD, 20 but another reported higher risk of PSP 25 in ET cases. However, several other clinicopathological studies found no excess risk of PD in ET cases. [15] [16] [17] If there were an exaggerated risk of PD or PSP in ET cases, shared genetic etiology would be a major consideration.
Clinical features of ET patients soon after the diagnosis of parkinsonism have been reported. 18, 19 Resting tremor and action tremor severity were greater in the ET-PD group than in the PD-only cases. 18 However, the entire clinical course in autopsied verified cases has not been studied.
We report our observations on longitudinally followed, autopsied ET cases that had a second diagnosis of parkinsonism.
Materials and Methods
Movement Disorders Clinic Saskatchewan (MDCS) has been conducted uninterrupted by the same one (A.H. R.) or two (A.H.R. and A.R.) movement disorders neurologists since 1968. All residents of Saskatchewan carry a general tax-funded provincial health care insurance. There is no direct cost to patients to attend the MDCS. Every MDCS patient is referred by a physician. A typical referral letter outlines the patient's problem and the reasons for consultation request. Movement disorders neurologists can follow their patients as they deem appropriate, without new referral request. Longitudinal follow-up of patients is of MDCS special interest. Patients are generally followed at a 6-to 12-month interval. 40, 41 At each clinic visit, the patient is evaluated by one or both movement disorders neurologists. We ask that one or more family members/caregivers accompany the patient, which adds credibility to the subjective data. There is no time restriction for clinical assessment of a patient at MDCS. More details of this program are provided in an open access publication. 41 At each clinic visit, severity of motor symptoms of parkinsonism and ET, treatment status, and drug adverse effects are documented. From 1968 to 1987, motor symptoms were evaluated using the Webster scale 42 and global parkinsonism-related disability by H & Y scale. 43 Subsequent to that, the UPDRS motor scale has been used. 44 To harmonize the 50-year clinical data, we classified the UPDRS tremor severity score: 1 = mild, 2 = moderate, and 3 and 4 = marked. The Mini-Mental State Examination is performed, where possible-approximately once a year. Videos are made on all consenting subjects, and sequential videos are made on some patients.
Diagnosis of ET was based on information provided by the referring physician, history provided by the patient/family, and clinical findings at the time of evaluation. ET was diagnosed when the patient had upper limb action tremor, with or without head tremor, which was not attributable to another neurological or systemic disorder. 16, 27, 29, 45 The second diagnosis of PS and of PD was made when all three major motor features-resting tremor, bradykinesia, and rigidity-were observed. 24 In some cases, the diagnosis of ET-PS was made by the referring physician and confirmed by the movement disorders neurologist. In all cases, the clinical features and diagnosis at initial MDCS assessment were noted. If the clinical picture of a patient changed during the follow-up at MDCS, which required revision to the diagnosis, the new clinical features that resulted in change of diagnosis were noted.
At an opportune time, a patient seen at MDCS is offered the choice of autopsy study at no cost to the family or estate of the patient. The patient is assured that this decision would not impact the ongoing care. It is encouraged that the patient take the declaration form home and discuss it with family before making that decision. This decision may be reversed by the patient at any time. If a patient decides against autopsy, he or she is never asked again. Autopsy is performed within 24 hours of death. The movement disorders neurologists are on 24/7 call for autopsy. The body is transported to the Royal University Hospital in Saskatoon for autopsy. Consent for the autopsy is approved by Saskatchewan Health Authority, and consent for use of brain tissue for research is approved by the Bioethics Board University of Saskatchewan. Immediately after removal, the brain is divided at midline. One half-brain is fixed in formalin for histological studies and the other half is frozen at -80 C. Neuropathology study is performed by a Canadian certified neuropathologist using stains, including alpha-synuclein, ubiquitin, and tau immunochemistry, as they became commercially available. 40 The neuropathologist has full access to patient clinical information at all times. The neuropathologist prepares a detailed report that is shared with the family, and an offer is made to discuss the findings with the neurologist if they so desire. 41 Final clinicopathological diagnosis is made by the treating neurologist, considering all clinical and neuropathology information. Original patient clinical records, videos, frozen brains, formalin brain remnants, pathology slides, and paraffin blocks are all preserved in our laboratory. 41 All ET patients seen at MDCS that came to autopsy between 1968 and 2018 were considered. Those patients that had a diagnosis of ET and subsequently developed parkinsonism and those in whom the clinical diagnosis of parkinsonism was not made, but had neuropathological findings of a known variant of parkinsonism, were included in this study. Drug-induced parkinsonism cases were excluded. 46 
Results
A total 589 patients followed at MDCS between 1968 and 2018 came to autopsy. Of those, 69 (12%) had a diagnosis of ET. Twenty-one (30%) of the ET patients that had either an additional clinical, or final clinicopathological diagnosis of ET-PS, were included in this study. In 5 cases, the diagnosis of ET-PS made by the referring physician was confirmed at the first MDCS assessment. Table 1 shows individual patient data pertinent to ET and parkinsonism, at the first MDCS visit. Where the initial MDCS diagnosis was revised during follow-up visits, the reasons are noted in Table 1 .
Median age of ET onset was 51 (6-71) years. Family history of tremor, ET, or parkinsonism was positive in 15 (71%) cases. This information was historical in most cases (Table 2) . In rare cases, the affected family member was assessed at MDCS (Table 1) . In most cases, such information was of a general nature, indicating presence of tremor without specific diagnosis. Median follow-up after first MDCS visit until death/autopsy was 7 (4-16) years. Mean duration of ET until the second diagnosis of PS was 30 (median 24; 4-62) years. Mean survival after ET onset was 38 (10-75) years (Table 2) . Table 3 is a summary of different clinicopathological diagnostic subgroups. The most common final clinicopathological diagnosis was ET-PD in 12 cases. Four patients, including 1 with ET-PD diagnosis, had the earlier tremor-dominant manifestations change, to akinetic-rigid during follow-up. 47 Video segment 1 shows a 71-year-old ET-PD patient. She had onset of ET at age 50 and the second diagnosis of PD at age 66. Video segment 2 shows an 81-year-old ET-PD case. He had onset of ET at age 21. The PD pathology was not predicted clinically in this case. He was evaluated several times. The last evaluation was 2 months before death, when the clinical picture was similar to that in the video.
The second largest subgroup was ET-PSP. It included 5 cases. Video segment 3 shows 1 such patient. He had onset of ET at age 60, and a second diagnosis of PD was made at age 87.
The spectrum of motor features at the final MDCS assessment in the ET-PD cases included: equal severity of resting tremor and bradykinesia/rigidity (mixed; Video, segment 1), tremor dominant (Video, segment 2), or akinetic-rigid (Video, segments 4a and 4b).
One patient had clinical diagnosis of ET-PD, but no pathological changes of a known PS variant. The neuropathologist was aware of the clinical diagnosis and conducted an extensive search. Only one alpha-synuclein-positive Lewy body was found in the amygdala. Other brain areas pertinent to PS were normal ( Table 1 , case 2).
One patient had ET and prominent cerebellar ataxia as well PD pathology, which was not predicted clinically. Another patient had clinical and pathological diagnosis of MSA. He had additional PD pathology, which was not predicted clinically ( Table 1 , case 3).
The most common error in predicting the underlying PS pathology was in 5 ET-PSP cases. Each of those patients was clinically diagnosed as ET-PD. None of them had ophthalmoplegia. We could not identify other clinical features that distinguished these ET-PSP cases from ET-PD cases (Supporting Information Table) .
Discussion
A major objective of neurology practice is making accurate clinical diagnosis; that is, especially applicable to movement disorders where the laboratory diagnostic tools are few and are not widely available. Diagnosis of ET is strictly clinical because there is no specific brain pathology in these patients. 1, 6, 17 Pathological findings characteristic of different PSs are, however, well known. 9, 10, 31 Thus, the clinical diagnosis of the underlying pathology of PS can be verified with neuropathology studies, for making the definite diagnosis. 9, 10, 31, 48 Resting tremor is a well-known feature of PS that also occurs in some ET-plus cases. 1, 16, 24, 28, 29, 35 Action tremor, which is characteristic of ET, 28, 29 is also a feature of PD. 36 Because of the overlapping tremor manifestations, clinical distinction between ET and PS can be difficult in some cases. 49, 50 Clinical diagnosis of PD in ET cases is even more challenging. Bradykinesia and rigidity are two major features of PS that are not part of the ET spectrum. Therefore, we used resting tremor, bradykinesia, and rigidity to make the second diagnosis of PS in ET patients.
Seventeen of 21 (81%) of our patients with known parkinsonian pathology were clinically recognized as having PS (Table 3 ). That figure is higher than reported in one study, where the patients were evaluated at multiple centers. 25 Only 3 of the 11 (27%) cases that had PSP pathology were recognized as having PS. A closer look at their data 25 shows that presence of bradykinesia and rigidity were the clinical features that helped make the additional diagnosis of PS.
Motor functions slow with normal aging. That may be mistaken as bradykinesia. In pre-existing ET and especially those who also have resting tremor, that may be mistaken for PD. The age-related slowing is symmetrical. 51 Asymmetrical bradykinesia, rigidity, and resting tremor is therefore a valuable indicator of PD in the elderly ET patients. 31, 51 Response to treatment and the prognosis vary in different PSs. 52 In general, there is greater benefit on levodopa and the prognosis is more favorable in PD than in PSP and MSA-the two other common Parkinson's variants. 52 Therefore, every effort is made to identify PD patients clinically.
Accuracy of clinical diagnosis of early-stage PD, reported in de novo patients, varies between 38% and 65%.
11 Sixteen of our 21 ET patients had a second clinical diagnosis of PD, which was confirmed at autopsy in 10 (63%; Table 3 ). The underlying pathology of all PS variants was accurately predicted in 12 of 21 (57%) patients. The most common error was a clinical diagnosis of PD in 5 patients who had PSP pathology. Similar errors have been reported by several other studies. 11, 25, 53 The main reason for that is the absence of ophthalmoplegia and early gait difficulty. 53 Recent literature indicates that PSP is more common than has been recognized so far. 11, 53 Such errors would likely continue until there are biomarkers that distinguish PD from PSP.
How the co-occurrence of PD in ET cases changes the clinical picture has been reported in some studies. 18, 19 Ryu and colleagues 18 reported that, with the onset of parkinsonism, these cases developed more pronounced action tremor and resting tremor. Minen and Louis 19 reported that all ET patients who developed parkinsonism had resting tremor and 94% to 96% had bradykinesia and rigidity respectively. Neither of these studies reported the entire clinical course as we have done. Our patients had a median follow-up that was 7 (4-16) years (Table 2 ) from the first MDCS visit until death. In some of our patients, who did not have evidence of PS at first assessment, but developed the parkinsonism during follow-up, we observed that both the resting tremor and the action tremor were more pronounced at the time of second diagnosis (Table 1) , confirming the observations of a previous study. 18 During follow-up visits, the clinical picture evolved in some cases. The resting tremor remained unchanged, declined, or fully resolved as seen in Video segments 4a and 4b. We did not observe a consistent pattern of change in action tremor in ET-PD cases during MDCS follow-up.
It has been reported that in the ET cases, PD more often starts on the side that has the most pronounced tremor. 6 We could not validate that. The first symptom of ET was reported as more common in the right than the left upper limb in our cases. One possible explanation is that most individuals are right handed and preferentially use that hand for daily life activities. They are more likely to note right than left upper limb action tremor. There are conflicting data about which PS variant is more common in ET cases. One clinical study observed that PD cases contrasted to PSP patients were more likely to have a previous diagnosis of ET. 54 Another report by the same group concluded that the risk of PSP was higher than of PD, in the ET cases. 25 The most common form of PS in our patients was PD, followed by PSP. Such relative frequency of PS variants is similar to that reported in other large autopsy series of PS. 11, 53 Our entire autopsy cohort has a similar pattern. 41 Our data show that all the common PS variants co-occur with ET. Which ET cases are predisposed to one or other Parkinson's variants needs further studies.
Family history of tremor, ET, or parkinsonism was positive in the majority (71%) of our cases. The significance of that cannot be interpreted accurately, given that the data, in most cases, are based on the information provided by patients/families and did not include specific diagnosis. Only a small number of family members with those disorders were evaluated by us (Table 1) .
Our study has some limitations. It is not a prospectively designed study to answer specific questions. It includes a small number-21 cases. The findings in our cases may not be applicable to all ET patients, because of referral and autopsy consent bias. The upper limb action tremor, which is typical of ET, can also be an early feature of PD, PSP, and other PS variants. Action tremor in such cases, without other motor feature of parkinsonism, cannot be distinguished from ET. We were unable to identify the optimal duration of isolated action tremor, before the second diagnosis of PS is entertained. We could not make a clinical diagnosis of PD in 2 cases that had prominent resting tremor but no bradykinesia or rigidity (Video, segment 2). In light of that, we recommend that, where possible, such ET patients have a PET or DaT study to distinguish PS form ET. Where that option is not available, the patient should be given a trial on L-dopa. We cannot explain the reason for some ET-PD patients remaining tremor dominant and others becoming akinetic-rigid. We are unable to identify the clinical features of ET cases that are predisposed to PD. The family history in our cases is not precise. We did not perform genetic studies. However, there are several strengths. This study is based on real-life practice of neurology. We have identified all the common degenerative Parkinson's variants in ET cases. Our patients had long follow-up and documented evolution of clinical features with time, and we have reported on the outcomes. It is the largest clinicopathological study of ET-PS cases to date.
In summary, in most ET cases, the PS manifests as bradykinesia, rigidity, and resting tremor. Except for PSP, most other PS variants can be clinically distinguished from PD. Clinical features of ET-PD cases evolve with time; resting tremor may resolve completely. Many PSP cases do not have ophthalmoplegia. The most common Parkinson's variant that co-occurs with ET is PD. The relative frequency of different PSs in this study is similar to that in unselected autopsy series.
The subspecialty clinics like ours offer an opportunity to conduct in-depth studies, but the patients enrolled are highly selective. Biomarkers of PD, ET, and PSP are needed to study the shared risk for ET and PS.
